Joshua Armenia, PhD, on Prostate Cancer: Recent Discoveries
2017 Genitourinary Cancers SymposiumJoshua Armenia, PhD, of Memorial Sloan Kettering Cancer Center, discusses new information that is changing the understanding of prostate cancer, including the identification of a new subclass, which represents 21% of cases, and the discovery of recurrently mutated cancer pathways not previously implicated in prostate cancer (Abstract 131).
Related Videos
Sumanta K. Pal, MD, on RCC and Tumor Profiling
Sumanta K. Pal, MD, of the City of Hope, discusses the evolution of circulating tumor DNA profile from first-line to second-line therapy in metastatic renal cell carcinoma. (Abstract ...
Joshua M. Lang, MD, on Prostate Cancer: Best of the Journals
Joshua M. Lang, MD, of the University of Wisconsin Carbone Cancer Center, discusses genomic alterations in DNA damage–repair pathways––more common in patients with prostate cancer tha...
Roland Seiler, MD, on Bladder Cancer: Subtypes and Treatment Response (German Language Version)
Roland Seiler, MD, of the University of British Columbia, discusses in German a way to identify molecular subtypes of muscle-invasive bladder cancer, the varying responses to cisplati...
George J. Bosl, MD, and Karim Fizazi, MD, PhD, on Germ Cell Tumors and Treatment Intensification: Pros and Cons
George J. Bosl, MD, of Memorial Sloan Kettering Cancer Center, and Karim Fizazi, MD, PhD, of Gustave Roussy and the University of Paris Sud, offer the “pro” and “con”...
Emma Hall, PhD, on Bladder Cancer: Results From the BC2001 Trial
Emma Hall, PhD, of the Institute of Cancer Research, London, discusses long-term outcomes with chemoradiotherapy vs radiotherapy alone, and standard vs reduced high-dose volume radiot...
